» Articles » PMID: 35093310

Emergence of SARS-CoV-2 Omicron (B.1.1.529) Variant, Salient Features, High Global Health Concerns and Strategies to Counter It Amid Ongoing COVID-19 Pandemic

Overview
Journal Environ Res
Publisher Elsevier
Date 2022 Jan 30
PMID 35093310
Authors
Affiliations
Soon will be listed here.
Abstract

Since the appearance in the late of December 2019, SARS-CoV-2 is rapidly evolving and mutating continuously, giving rise to various variants with variable degrees of infectivity and lethality. The virus that initially appeared in China later mutated several times, wreaking havoc and claiming many lives worldwide amid the ongoing COVID-19 pandemic. After Alpha, Beta, Gamma, and Delta variants, the most recently emerged variant of concern (VOC) is the Omicron (B.1.1.529) that has evolved due to the accumulation of high numbers of mutations especially in the spike protein, raising concerns for its ability to evade from pre-existing immunity acquired through vaccination or natural infection as well as overpowering antibodies-based therapies. Several theories are on the surface to explain how the Omicron has gathered such a high number of mutations within less time. Few of them are higher mutation rates within a subgroup of population and then its introduction to a larger population, long term persistence and evolution of the virus in immune-compromised patients, and epizootic infection in animals from humans, where under different immune pressures the virus mutated and then got reintroduced to humans. Multifaceted approach including rapid diagnosis, genome analysis of emerging variants, ramping up of vaccination drives and receiving booster doses, efficacy testing of vaccines and immunotherapies against newly emerged variants, updating the available vaccines, designing of multivalent vaccines able to generate hybrid immunity, up-gradation of medical facilities and strict implementation of adequate prevention and control measures need to be given high priority to handle the on-going SARS-CoV-2 pandemic successfully.

Citing Articles

SARS-CoV-2 Variants: Genetic Insights, Epidemiological Tracking, and Implications for Vaccine Strategies.

Alhamlan F, Al-Qahtani A Int J Mol Sci. 2025; 26(3).

PMID: 39941026 PMC: 11818319. DOI: 10.3390/ijms26031263.


SARS-CoV-2 evolution on a dynamic immune landscape.

Raharinirina N, Gubela N, Bornigen D, Smith M, Oh D, Budt M Nature. 2025; 639(8053):196-204.

PMID: 39880955 PMC: 11882442. DOI: 10.1038/s41586-024-08477-8.


Variation and evolution analysis of SARS-CoV-2 using self-game sequence optimization.

Liu Z, Shen Y, Jiang Y, Zhu H, Hu H, Kang Y Front Microbiol. 2024; 15:1485748.

PMID: 39588108 PMC: 11586374. DOI: 10.3389/fmicb.2024.1485748.


Risk Factors for Secondary Organizing Pneumonia and Acute Fibrinous and Organizing Pneumonia in Patients with COVID-19 Pneumonia.

Aikwanich A, Eksombatchai D, Petnak T, Tassaneeyasin T, Boonsarngsuk V Infect Drug Resist. 2024; 17:5017-5026.

PMID: 39554470 PMC: 11566205. DOI: 10.2147/IDR.S481540.


Genomic epidemiology and evolutionary dynamics of the Omicron variant of SARS-CoV-2 during the fifth wave of COVID-19 in Pakistan.

Razzaq A, Disoma C, Iqbal S, Nisar A, Hameed M, Qadeer A Front Cell Infect Microbiol. 2024; 14:1484637.

PMID: 39502171 PMC: 11534695. DOI: 10.3389/fcimb.2024.1484637.


References
1.
Brandal L, MacDonald E, Veneti L, Ravlo T, Lange H, Naseer U . Outbreak caused by the SARS-CoV-2 Omicron variant in Norway, November to December 2021. Euro Surveill. 2021; 26(50). PMC: 8728491. DOI: 10.2807/1560-7917.ES.2021.26.50.2101147. View

2.
Kutscher E . Preparing for Omicron as a covid veteran. BMJ. 2021; 375:n3021. DOI: 10.1136/bmj.n3021. View

3.
Kupferschmidt K . Scientists see a 'really, really tough winter' with Omicron. Science. 2021; 374(6574):1421-1422. DOI: 10.1126/science.acz9834. View

4.
Kozlov M . Omicron overpowers key COVID antibody treatments in early tests. Nature. 2021; . DOI: 10.1038/d41586-021-03829-0. View

5.
Callaway E . Heavily mutated Omicron variant puts scientists on alert. Nature. 2021; 600(7887):21. DOI: 10.1038/d41586-021-03552-w. View